Retinitis pigmentosa is a group of rare genetic disorders, characterized by the breakdown and loss of cells in the retina of eye. Retinitis pigmentosa is familial, inherited in a variety of ways, including dominant, recessive, and sex-linked recessive. The symptoms of the disease include, loss of night vision, gradual loss of central and peripheral vision, and problems with color vision, difficulty in the daily activities such as reading, driving, walking, and reorganization of the faces and objects. Retinitis pigmentosa can be diagnosed by the electroretinogram (ERG), and visual field testing and genetic testing. Proretina Therapeutics, S.L. is in the process of developing PRO-001 and PRO-015 as a neuroprotective agent and gene therapy, respectively, for the treatment of retinitis pigmentosa.
RETINITIS PIGMENTOSA THERAPEUTICS DRUG CANDIDATES UNDER DEVELOPMENT (2017)
As of November 2017, the retinitis pigmentosa therapeutics pipeline comprises of 38 drug candidates in different stages of development.
Some of the players developing drugs for the treatment of retinitis pigmentosa include jCyte, Inc., Dompe Farmaceutici SpA, ProRetina Therapeutics, S.L., and Recursion Pharmaceuticals Inc.